Alpha Tau Medical Reports Long-Term Safety And Efficacy Data From Multiple Clinical Trials Of Alpha DaRT
Portfolio Pulse from Benzinga Newsdesk
Alpha Tau Medical has reported long-term safety and efficacy data from multiple clinical trials of Alpha DaRT. The company stated that 81 lesions treated across four feasibility trials of head and neck or skin cancers demonstrated an 89% complete response rate.
August 17, 2023 | 9:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alpha Tau Medical's positive clinical trial results could potentially boost investor confidence in DRTS.
Positive clinical trial results often lead to increased investor confidence as they indicate potential future success of the product. This could lead to an increase in the stock price of DRTS in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100